Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Detection of Ultrahigh Energy Emission from Gamma-Ray Binary LS I +61° 303.

Physical review letters·2026
Same author

Evidence of Cosmic-Ray Acceleration up to Sub-PeV Energies in the Supernova Remnant IC 443.

Physical review letters·2026
Same author

Precise Measurement of the Cosmic Ray Helium Spectrum above 0.1 PeV.

Physical review letters·2026
Same author

All-Sky Search for Individual Primordial Black Hole Bursts with LHAASO.

Physical review letters·2025
Same author

Measurement of Very-High-Energy Diffuse Gamma-Ray Emissions from the Galactic Plane with LHAASO-WCDA.

Physical review letters·2025
Same author

Stringent Tests of Lorentz Invariance Violation from LHAASO Observations of GRB 221009A.

Physical review letters·2024
Same journal

Erratum to: Immunotherapeutic Approach to Cancer with Cutaneous DNA Vaccination.

Methods in molecular medicine·2015
Same journal

Methods for cancer gene therapy using tumor suppressor genes.

Methods in molecular medicine·2014
Same journal

Suppression of the human carcinoma phenotype by an antioncogene ribozyme.

Methods in molecular medicine·2014
Same journal

Methods for the use of stromal cells for therapeutic gene therapy.

Methods in molecular medicine·2014
Same journal

Methods for adenovirus-mediated gene transfer to synovium in vivo.

Methods in molecular medicine·2014
Same journal

Methods for gene transfer to synovium.

Methods in molecular medicine·2014
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

E1A-Mediated Gene Therapy.

M C Hung1, D H Yan, S Zhang

  • 1Department of Cancer Biology, Section of Moecular Cell Biology and Department of Surgical Oncology, The University of Texas, Houston, TX.

Methods in Molecular Medicine
|February 23, 2011
PubMed
Summary
This summary is machine-generated.

Ovarian cancer is a deadly disease due to late detection and ineffective treatments. Targeting the HER-2 (human epidermal growth factor receptor 2) gene, often overexpressed in ovarian tumors, offers a promising therapeutic strategy.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Related Experiment Videos

Last Updated: Jun 4, 2026

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness
06:21

An Ecdysone Receptor-based Singular Gene Switch for Deliberate Expression of Transgene with Robustness, Reversibility, and Negligible Leakiness

Published on: May 7, 2018

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian carcinoma is the leading cause of gynecologic cancer deaths.
  • Late detection and resistance to chemotherapy contribute to high mortality rates.
  • HER-2 (human epidermal growth factor receptor 2) gene amplification/overexpression is common in ovarian cancers.

Purpose of the Study:

  • To investigate HER-2 as a therapeutic target in ovarian cancer.
  • To explore the role of HER-2 in chemoresistance and metastasis.

Main Methods:

  • Analysis of HER-2 gene amplification/overexpression in ovarian cancer.
  • Experimental systems to assess HER-2's impact on chemotherapy response.
  • Model systems to evaluate HER-2's role in metastasis.

Main Results:

  • HER-2 overexpression is a frequent pathological feature in ovarian cancers.
  • HER-2 overexpression correlates with increased resistance to chemotherapy.
  • HER-2 overexpression enhances the metastatic potential of cancer cells.

Conclusions:

  • The HER-2 gene is a viable therapeutic target for ovarian cancer.
  • Targeting HER-2 may help overcome chemoresistance and reduce metastasis.
  • Developing HER-2-targeted agents could reverse malignant transformation in ovarian cancer.